Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 11.32
CERS's Cash to Debt is ranked lower than
57% of the 839 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. CERS: 11.32 )
Ranked among companies with meaningful Cash to Debt only.
CERS' s 10-Year Cash to Debt Range
Min: 0.62  Med: 121.00 Max: 14206.57
Current: 11.32
0.62
14206.57
Equity to Asset 0.77
CERS's Equity to Asset is ranked higher than
62% of the 587 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CERS: 0.77 )
Ranked among companies with meaningful Equity to Asset only.
CERS' s 10-Year Equity to Asset Range
Min: 0.06  Med: 0.67 Max: 0.9
Current: 0.77
0.06
0.9
F-Score: 3
Z-Score: 4.03
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -137.01
CERS's Operating margin (%) is ranked lower than
58% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -71.51 vs. CERS: -137.01 )
Ranked among companies with meaningful Operating margin (%) only.
CERS' s 10-Year Operating margin (%) Range
Min: -2168.13  Med: -188.90 Max: -7.75
Current: -137.01
-2168.13
-7.75
Net-margin (%) -132.42
CERS's Net-margin (%) is ranked lower than
58% of the 655 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. CERS: -132.42 )
Ranked among companies with meaningful Net-margin (%) only.
CERS' s 10-Year Net-margin (%) Range
Min: -1946.68  Med: -194.91 Max: 53.6
Current: -132.42
-1946.68
53.6
ROE (%) -83.37
CERS's ROE (%) is ranked lower than
76% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. CERS: -83.37 )
Ranked among companies with meaningful ROE (%) only.
CERS' s 10-Year ROE (%) Range
Min: -248.74  Med: -80.78 Max: 46.03
Current: -83.37
-248.74
46.03
ROA (%) -52.80
CERS's ROA (%) is ranked lower than
71% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -26.31 vs. CERS: -52.80 )
Ranked among companies with meaningful ROA (%) only.
CERS' s 10-Year ROA (%) Range
Min: -122.82  Med: -46.70 Max: 16.26
Current: -52.8
-122.82
16.26
ROC (Joel Greenblatt) (%) -961.56
CERS's ROC (Joel Greenblatt) (%) is ranked lower than
60% of the 815 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. CERS: -961.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CERS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8770.57  Med: -1271.73 Max: 36.35
Current: -961.56
-8770.57
36.35
Revenue Growth (3Y)(%) -11.40
CERS's Revenue Growth (3Y)(%) is ranked lower than
61% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CERS: -11.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CERS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -44.7  Med: 8.80 Max: 52.9
Current: -11.4
-44.7
52.9
EBITDA Growth (3Y)(%) 15.70
CERS's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 430 Companies
in the Global Biotechnology industry.

( Industry Median: -3.50 vs. CERS: 15.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CERS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -52.9  Med: 6.20 Max: 123.5
Current: 15.7
-52.9
123.5
EPS Growth (3Y)(%) 14.10
CERS's EPS Growth (3Y)(%) is ranked higher than
71% of the 411 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CERS: 14.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CERS' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.1  Med: 2.30 Max: 21
Current: 14.1
-30.1
21
» CERS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CERS Guru Trades in Q2 2014

Chuck Royce 3,725,505 sh (-2.14%)
» More
Q3 2014

CERS Guru Trades in Q3 2014

Chuck Royce 3,765,505 sh (+1.07%)
» More
Q4 2014

CERS Guru Trades in Q4 2014

Ron Baron 28,100 sh (New)
Chuck Royce 3,455,505 sh (unchged)
Chuck Royce 3,455,505 sh (-8.23%)
» More
Q1 2015

CERS Guru Trades in Q1 2015

PRIMECAP Management 7,300,000 sh (New)
Jim Simons 136,000 sh (New)
PRIMECAP Management 5,800,000 sh (New)
Ron Baron 133,400 sh (+374.73%)
Chuck Royce 3,145,505 sh (-8.97%)
» More
» Details

Insider Trades

Latest Guru Trades with CERS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.30
CERS's P/B is ranked higher than
52% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. CERS: 4.30 )
Ranked among companies with meaningful P/B only.
CERS' s 10-Year P/B Range
Min: 0.82  Med: 5.59 Max: 55
Current: 4.3
0.82
55
P/S 11.08
CERS's P/S is ranked higher than
55% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 14.66 vs. CERS: 11.08 )
Ranked among companies with meaningful P/S only.
CERS' s 10-Year P/S Range
Min: 1.24  Med: 6.00 Max: 15.91
Current: 11.08
1.24
15.91
Current Ratio 5.99
CERS's Current Ratio is ranked higher than
59% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CERS: 5.99 )
Ranked among companies with meaningful Current Ratio only.
CERS' s 10-Year Current Ratio Range
Min: 1.03  Med: 3.69 Max: 9.96
Current: 5.99
1.03
9.96
Quick Ratio 5.29
CERS's Quick Ratio is ranked higher than
57% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CERS: 5.29 )
Ranked among companies with meaningful Quick Ratio only.
CERS' s 10-Year Quick Ratio Range
Min: 1.03  Med: 3.00 Max: 9.96
Current: 5.29
1.03
9.96
Days Inventory 232.49
CERS's Days Inventory is ranked lower than
79% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 116.85 vs. CERS: 232.49 )
Ranked among companies with meaningful Days Inventory only.
CERS' s 10-Year Days Inventory Range
Min: 122.1  Med: 217.08 Max: 343.01
Current: 232.49
122.1
343.01
Days Sales Outstanding 51.90
CERS's Days Sales Outstanding is ranked higher than
60% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. CERS: 51.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
CERS' s 10-Year Days Sales Outstanding Range
Min: 0.3  Med: 65.46 Max: 256.86
Current: 51.9
0.3
256.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.16
CERS's Price/Net Cash is ranked higher than
61% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 8.97 vs. CERS: 6.16 )
Ranked among companies with meaningful Price/Net Cash only.
CERS' s 10-Year Price/Net Cash Range
Min: 1.88  Med: 6.77 Max: 103.13
Current: 6.16
1.88
103.13
Price/Net Current Asset Value 4.68
CERS's Price/Net Current Asset Value is ranked higher than
68% of the 572 Companies
in the Global Biotechnology industry.

( Industry Median: 8.11 vs. CERS: 4.68 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CERS' s 10-Year Price/Net Current Asset Value Range
Min: 1.17  Med: 7.29 Max: 317.86
Current: 4.68
1.17
317.86
Price/Tangible Book 4.47
CERS's Price/Tangible Book is ranked higher than
58% of the 702 Companies
in the Global Biotechnology industry.

( Industry Median: 5.88 vs. CERS: 4.47 )
Ranked among companies with meaningful Price/Tangible Book only.
CERS' s 10-Year Price/Tangible Book Range
Min: 0.92  Med: 6.68 Max: 300
Current: 4.47
0.92
300
Price/Median PS Value 1.83
CERS's Price/Median PS Value is ranked lower than
73% of the 548 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. CERS: 1.83 )
Ranked among companies with meaningful Price/Median PS Value only.
CERS' s 10-Year Price/Median PS Value Range
Min: 0.24  Med: 1.55 Max: 90.66
Current: 1.83
0.24
90.66
Earnings Yield (Greenblatt) (%) -12.80
CERS's Earnings Yield (Greenblatt) (%) is ranked lower than
66% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CERS: -12.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CERS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -15.6  Med: 295.10 Max: 2848.7
Current: -12.8
-15.6
2848.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU2.Germany,
Cerus Corp was incorporated in California on September 19, 1991 and reincorporated in Delaware in 1996. It is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has rights for its INTERCEPT Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received CE marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, or CIS, the Middle East and selected countries in other regions around the world. The Company sells both the platelet and plasma systems using its direct sales force and through distributors. Company continue to use, third parties to manufacture and supply the devices, disposable kits and inactivation compounds that make up the INTERCEPT Blood System for use in clinical trials and for commercialization. The Company owns approximately 15 issued or allowed United States patents and approximately 121 issued or allowed foreign patents related to the INTERCEPT Blood System. The market for the INTERCEPT Blood System is subjected by a relatively small number of blood collection organizations. Many of these organizations are national blood transfusion services or Red Cross organizations who collect, store and distribute virtually all of their respective nations' blood and blood component supplies. The European markets for its products are in Germany, France, and England. The Company and its products are comprehensively regulated in the United States by the FDA and, in some instances, by state and local governments, and by comparable governmental authorities in other countries.
» More Articles for CERS

Headlines

Articles On GuruFocus.com
hummm royce adding Oct 05 2011 
Cerus Corp. Reports Operating Results (10-K) Mar 16 2011 
Cerus Corp. Reports Operating Results (10-Q) Aug 16 2010 
Cerus Corp. Reports Operating Results (10-Q) May 12 2010 
Cerus Corp. Reports Operating Results (10-Q) Nov 06 2009 
Cerus Corporation Announces Second Quarter Financial Results Jul 30 2009 
Cerus Corporation Extends Manufacturing Agreement with Fenwal Dec 15 2008 

More From Other Websites
Cerus to Present at Cantor Fitzgerald’s Inaugural Healthcare Conference on July 8, 2015 Jul 01 2015
First INTERCEPT Pathogen Reduced Platelet Units Produced in the Continental US Jun 29 2015
CERUS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 15 2015
Richard J. Benjamin, MD PhD Appointed as Cerus Corporation’s New Chief Medical Officer Jun 08 2015
Richard J. Benjamin, MD PhD Appointed as Cerus Corporation’s New Chief Medical Officer Jun 08 2015
Sell These 7 Health Care Supplies Companies Now Jun 04 2015
5 Stocks Under $10 Ready to Spike Higher May 29 2015
CERUS CORP Financials May 15 2015
10-Q for Cerus Corp. May 10 2015
CERUS CORP Files SEC form 10-Q, Quarterly Report May 08 2015
Cerus Corporation Reports First Quarter 2015 Results May 05 2015
Cerus reports 1Q loss May 05 2015
Cerus reports 1Q loss May 05 2015
CERUS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 05 2015
Cerus Corporation Reports First Quarter 2015 Results May 05 2015
Q1 2015 Cerus Corp Earnings Release - After Market Close May 05 2015
10-K for Cerus Corp. May 03 2015
Cerus to Present at AABB Symposium on Pathogen-Reduced Components Apr 27 2015
Cerus to Present at AABB Symposium on Pathogen-Reduced Components Apr 27 2015
Cerus to Release First Quarter 2015 Results on May 5, 2015 Apr 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK